|

Consolidating Plant Medicine, Permaculture and Indigenous Wisdom With Colette Condorcita, Decriminalize Philadelphia

Similar Posts

  • Interview With Ronan Levy

    In this episode of the Psychedelic Spotlight podcast, we catch up with Ronan Levy, Co-Founder and Executive Chairman of Field Trip Health, and discuss the significance behind the company’s recent opening of its psilocybin research and cultivation facility in Jamaica along with the company’s recent listing on the OTCQX.

  • NUMI Stock Deep Dive [ Will Numinus Wellness be a Leader in The Shroom BOOM?] 🤔

    What’s up psychedelic investors! Today we’re finally going to cover the long anticipated NUMIStock. Numinus Wellness is a psychedelic Medicines company using a variety of compounds like psilocybin, MDMA and ketamine to treat for addiction, PTSD, depression and more. You can find the NUMI Stock on the TSX Venture exchange under the ticker symbol NUMI. NUMI stock is currently trading around 1$ Canadian, with a market cap of around $200 million. If you don’t want to purchase NUMI individually, Numinus can also be partially owned through an ETF like Horizons Psychedelic Stock Index or the upcoming Advisor Shares Plant Medicine ETF.

    In this video we will cover the problems Numinus is trying to solve, their flagship programs, their financials, and finally the risks for the company. Numinus Wellness is one of the first psychedelic stocks we covered on this channel and the company has advanced quite nicely in the past few months, making it an interesting pick for the shroom boom!

    Time Stamps
    0:00 – Intro
    1:20 – What Problem is Numinus trying to solve?
    3:22 – NuMi Ketamine Treatments for Depression
    4:50 – MDMA to treat PTSD
    6:24 – Numinus Wellness Treating Addiction with Psilocybin
    7:48 – Special Access Trials for MDMA and Psilocybin
    9:02 – Psilocybin Extraction from Magic Mushrooms
    9:39 – Financials and Cash on Hand
    11:29 – Risks

    https://www.newswire.ca/news-releases/numinus-wellness-closes-q1-2021-with-strong-cash-position-and-industry-firsts-867457159.html?fbclid=IwAR3gKruRdmOGIBZeRmS_xU-R_0J4WehW5TodKLx7SWK19DdpEeoZhM8O-2c#:~:text=Achievedcashbalanceof4915209,(1928737)forQ12021

    So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    If you want to collaborate, send us an email!
    thepsychedelicinvestor@gmail.com

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa
    ​…

    https://benzinga.grsm.io/thepsychedel
    ​…

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #NuminusWellness #NUMIStock #MindMed

  • BUY Ratings, New Partnerships & Government Awards ( Mydecine, ENBI, SILO, DMT, BRAXIA, DRUG)

    NEW BUY RATINGS, More Partnerships and Government Awards for psychedelic inspired companies! In this episode, we’ll take a look at the smaller psychedelic medicine companies such as Mydecine, Entheon Biomedical, Braxia, Small Pharma, Silo Therapeutics and Bright Minds Sciences.

    Enjoy the episode!

    Timestamps:

    0:00 – Intro
    0:44 – Mydecine (MYCO/ MYCOF) Unveils Artificial Intelligence Drug Discovery Program
    2:21 – Braxia Scientific (OTC:BRAXF, CSE: BRAX) Awarded Government of Canada Funding To Complete The First Ever Ketamine Clinical Trial Testing For Bipolar Depression
    3:51 – Partnership Between Entheon / SILO Pharma (OTC:ENTBF, CSE:ENBI) (OTC: SILO)
    6:59 – Bright Minds (OTC: BMBIF, CSE: DRUG) Announces Application to List on Nasdaq
    8:43 – Small Pharma (TSXV: DMT) – Price Target of C$5

    Links:

    Mydecine (OTC: MYCOF, NEO: MYCO) Unveils Artificial Intelligence Drug Discovery Program, in conjunction with the University of Alberta:
    https://www.psychedelicfinance.com/articles/mydecine-unveils-artificial-intelligence-drug-discovery-program

    Braxia Scientific (OTC:BRAXF, CSE: BRAX) Awarded Government of Canada Funding To Complete The First Ever Ketamine Clinical Trial Testing For Bipolar Depression:
    https://braxiascientific.com/news/braxia-scientific-awarded-government-of-canada-funding-to-complete-first-of-its-kind-ketamine-clinical-trial-for-bipolar-depression/

    Partnership Between Entheon / SILO Pharma (OTC:ENTBF, CSE:ENBI) (OTC: SILO):
    https://thecannabisstock.com/2021/06/17/entheon-biomedicals-wholly-owned-subsidiary-halugen-life-sciences-and-silo-wellness-announces-psychedelics-genetic-test-kit-partnership/

    Bright Minds (OTC: BMBIF, CSE: DRUG) Announces Application to List on Nasdaq:
    https://psilocybinalpha.com/news/bright-minds-biosciences-announces-application-to-list-on-nasdaq

    Small Pharma (TSXV: DMT) – Roth Capital Initiates Coverage On Small Pharma with Buy Rating, Announces Price Target of C$5:
    https://www.benzinga.com/news/21/06/21452074/roth-capital-initiates-coverage-on-small-pharma-with-buy-rating-announces-price-target-of-c-5

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Website: https://thepsychedelicinvestor.com/
    Music: www.bensound.com
    editing:@themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Mydecine #Entheon #MYCO

  • LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]

    Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
    So make sure you stick around for both.

    Timecodes:
    0:00 – Intro
    3:30 – New Phase 1 Clinical Trial
    9:45 – Changes in Leadership
    13:19 – New MindMed Partnership
    20:30 – Conclusion

    So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?

    First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.

    Why combine these two substances?
    What diseases could it help alleviate?
    And what is the timeline for this project?

    Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.

    Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.

    Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.

    Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.

    Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
    We talked about all sorts of interesting topics and I had a great time.

    I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
    https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
    https://www.instagram.com/sena__maria/

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video from Pexels

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMEDF #MindmedStock